Short Interest in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Decreases By 86.8%

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) saw a significant decline in short interest during the month of April. As of April 30th, there was short interest totaling 169 shares, a decline of 86.8% from the April 15th total of 1,276 shares. Based on an average daily volume of 5,628 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company’s stock are sold short.

Institutional Investors Weigh In On Invesco Biotechnology & Genome ETF

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Q3 Asset Management purchased a new position in Invesco Biotechnology & Genome ETF during the 4th quarter worth $1,431,000. Northwestern Mutual Wealth Management Co. raised its position in shares of Invesco Biotechnology & Genome ETF by 9,169.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 342,971 shares of the company’s stock valued at $28,175,000 after purchasing an additional 339,271 shares during the last quarter. Western Wealth Management LLC purchased a new position in shares of Invesco Biotechnology & Genome ETF in the 4th quarter valued at approximately $224,000. RFG Advisory LLC raised its position in shares of Invesco Biotechnology & Genome ETF by 6.6% in the 4th quarter. RFG Advisory LLC now owns 8,455 shares of the company’s stock valued at $695,000 after purchasing an additional 521 shares during the last quarter. Finally, Comerica Bank raised its position in shares of Invesco Biotechnology & Genome ETF by 86.2% in the 4th quarter. Comerica Bank now owns 378 shares of the company’s stock valued at $31,000 after purchasing an additional 175 shares during the last quarter.

Invesco Biotechnology & Genome ETF Stock Performance

NYSEARCA:PBE traded down $0.70 during midday trading on Thursday, reaching $82.41. 3,592 shares of the stock traded hands, compared to its average volume of 6,785. Invesco Biotechnology & Genome ETF has a 12-month low of $59.75 and a 12-month high of $85.73. The business has a 50-day moving average of $79.42 and a two-hundred day moving average of $80.40. The stock has a market capitalization of $256.30 million, a PE ratio of 20.44 and a beta of 0.71.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.